Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin

Paolo Prandoni, Anthonie W. A. Lensing, Martin H. Prins, Martin Gebel, Akos F. Pap, Martin Homering, Rupert Bauersachs, Jan Beyer-Westendorf, Henri Bounameaux, Alexander T. Cohen, Bruce L. Davidson, Bonno van Bellen, Peter Verhamme, Philip S. Wells, Zhong Yuan, Bennett Levitan, Jeffrey I. Weitz*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)121-129
Number of pages9
JournalThrombosis Research
Volume168
DOIs
Publication statusPublished - 1 Aug 2018

Keywords

  • INTENSITY WARFARIN THERAPY
  • LONG-TERM
  • NONSURGICAL PATIENTS
  • ATRIAL-FIBRILLATION
  • PREVENTION
  • DISEASE
  • ANTICOAGULANTS
  • COMPLICATIONS
  • DEFINITION
  • THROMBOSIS

Cite this